{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:42:19Z","timestamp":1792784539121,"version":"4.5.0"},"reference-count":34,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["YG2026QNB45"],"award-info":[{"award-number":["YG2026QNB45"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Fund of Hongqiao International Institute of Medicine, Shanghai Jiao Tong University School of Medicine","award":["HQYJY-2025-14"],"award-info":[{"award-number":["HQYJY-2025-14"]}],"id":[{"id":"https:\/\/ror.org\/0220qvk04","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Science and Technology Commission of Shanghai Municipality","award":["20DZ2254900"],"award-info":[{"award-number":["20DZ2254900"]}],"id":[{"id":"https:\/\/ror.org\/03kt66j61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Science and Technology Commission of Shanghai Municipality","award":["23520712500"],"award-info":[{"award-number":["23520712500"]}],"id":[{"id":"https:\/\/ror.org\/03kt66j61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine","award":["2023DHYGJC-ZDB01"],"award-info":[{"award-number":["2023DHYGJC-ZDB01"]}],"id":[{"id":"https:\/\/ror.org\/0220qvk04","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["81972574"],"award-info":[{"award-number":["81972574"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["U23A2096"],"award-info":[{"award-number":["U23A2096"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["W2421104"],"award-info":[{"award-number":["W2421104"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Project of Leading Talents of Tongren Hospital","award":["TRKYRC-lj202205"],"award-info":[{"award-number":["TRKYRC-lj202205"]}],"id":[{"id":"https:\/\/ror.org\/01r8rcr36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma and remains challenging to treat at advanced stages due to immune evasion and inefficient intracellular delivery of therapeutic agents. In this study, we synthesized a modified generation 5 (G5) poly(amidoamine) dendrimer (G5PBA) to co-deliver small-interfering RNA targeting programmed death-ligand 1 (siPD-L1) and the antitumor peptide Tat-HSPB1, forming the G5PBA\/siPD-L1\/Tat-HSPB1 nanocomplex. The agarose gel retardation assay demonstrated that G5PBA efficiently condensed siPD-L1. Furthermore, the peptide encapsulation efficiency and loading capacity were measured, confirming the loading of Tat-HSPB1 into G5PBA\/siPD-L1. Flow cytometry showed that G5PBA enhanced the cellular uptake of siPD-L1, while confocal microscopy demonstrated that G5PBA promoted lysosomal escape in Caki-1 cells. Western blot analysis further confirmed that G5PBA effectively reduced the PD-L1 protein expression. In cellular experiments, CCK-8, EdU, and wound-healing assays demonstrated that G5PBA\/siPD-L1\/Tat-HSPB1 inhibited the viability and migration of ccRCC cells. G5PBA\/siPD-L1\/Tat-HSPB1 suppressed tumor growth, downregulated PD-L1 expression, enhanced CD4+ and CD8+ T-cell infiltration, and elevated serum levels of IL-2, IL-6, TNF-\u03b1, and IFN-\u03b3 in mice. Major organs exhibited no obvious histopathological abnormalities upon H&amp;E staining. Serum ALT, AST, and BUN levels showed no significant changes compared with the PBS group, suggesting the preliminary safety profile of G5PBA\/siPD-L1\/Tat-HSPB1. Collectively, the nanocomplex achieved efficient peptide\/siPD-L1 co-delivery and demonstrated significant antitumor activity. This system thus provides a promising strategy and experimental basis for local administration of ccRCC.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00488","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:02:03Z","timestamp":1790204523000},"page":"2101-2112","source":"Crossref","is-referenced-by-count":0,"title":["Co-delivery of siPD-L1 and Tat-HSPB1 by G5PBA Enhances the Efficacy of Antitumor Therapy in Clear Cell Renal Cell Carcinoma"],"prefix":"10.1021","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7118-4095","authenticated-orcid":true,"given":"Kui","family":"Xiong","sequence":"first","affiliation":[{"name":"Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200336"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Xia","sequence":"additional","affiliation":[{"name":"Donghua University , , ,","place":["Shanghai, China, 201620"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200336"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University School of Medicine , , No. 1111, Xianxia Road , ,","place":["Shanghai, China, 200336"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"An","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University School of Medicine , , ,","place":["Shanghai, China, 200336"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-6645","authenticated-orcid":true,"given":"Xiangyang","family":"Shi","sequence":"additional","affiliation":[{"name":"Donghua University , , ,","place":["Shanghai, China, 201620"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Zhi","family":"Jin","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University School of Medicine , , No. 1111, Xianxia Road , ,","place":["Shanghai, China, 200336"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"3","key":"2026102103084565500_cit1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-Cancer J. Clin."},{"issue":"1","key":"2026102103084565500_cit2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur. Urol."},{"issue":"5","key":"2026102103084565500_cit3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 Update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"issue":"1","key":"2026102103084565500_cit4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/cam4.3596","article-title":"Patterns of distant metastases in patients with clear cell renal cell carcinoma--A population-based analysis","volume":"10","author":"Xue","year":"2021","journal-title":"Cancer Med."},{"key":"2026102103084565500_cit5","doi-asserted-by":"publisher","first-page":"1133832","DOI":"10.3389\/fonc.2023.1133832","article-title":"Treatment strategies for clear cell renal cell carcinoma: Past, present and future","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"2026102103084565500_cit6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"2026102103084565500_cit7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/nejmoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"2026102103084565500_cit8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann. Oncol."},{"issue":"3","key":"2026102103084565500_cit9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.20892\/j.issn.2095-3941.2020.0704","article-title":"Strategies to enhance monoclonal antibody uptake and distribution in solid tumors","volume":"18","author":"Bordeau","year":"2021","journal-title":"Cancer Biol. Med."},{"issue":"10","key":"2026102103084565500_cit10","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/cells10102734","article-title":"siRNA nanoparticle targeting PD-L1 activates tumor immunity and abrogates pancreatic cancer growth in humanized preclinical model","volume":"10","author":"Jung","year":"2021","journal-title":"Cells"},{"issue":"1","key":"2026102103084565500_cit11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12951-025-03170-y","article-title":"Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"20","key":"2026102103084565500_cit12","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.3390\/molecules28207165","article-title":"Peptides as therapeutic agents: challenges and opportunities in the Green Transition Era","volume":"28","author":"Rossino","year":"2023","journal-title":"Molecules"},{"issue":"28","key":"2026102103084565500_cit13","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/jco.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"2026102103084565500_cit14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/nejmoa1316158","article-title":"Lanreotidein metastaticenteropancreaticneuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"2026102103084565500_cit15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/cdd.2016.35","article-title":"The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade","volume":"23","author":"Yamazaki","year":"2016","journal-title":"Cell Death Differ."},{"issue":"7","key":"2026102103084565500_cit16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tips.2023.04.003","article-title":"Recent advances in the development of therapeutic peptides","volume":"44","author":"Fetse","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"10","key":"2026102103084565500_cit17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ph15101283","article-title":"Strategies for improving peptide stability and delivery","volume":"15","author":"Al Musaimi","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"18","key":"2026102103084565500_cit18","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.3390\/molecules25184245","article-title":"Peptides with dual antimicrobial-anticancer activity: strategies to overcome peptide limitations and rational design of anticancer peptides","volume":"25","author":"Liscano","year":"2020","journal-title":"Molecules"},{"issue":"22","key":"2026102103084565500_cit19","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.3390\/cancers14225710","article-title":"Tat-HSPB1 Suppresses clear cell renal cell carcinoma growth via lysosomal membrane permeabilization","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"2026102103084565500_cit20","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.3390\/molecules23112849","article-title":"New advances in general biomedical applications of PAMAM dendrimers","volume":"23","author":"Arau\u0301jo","year":"2018","journal-title":"Molecules"},{"key":"2026102103084565500_cit21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1472-6750-9-38","article-title":"Acetylation of PAMAM dendrimers for cellular delivery of siRNA","volume":"9","author":"Waite","year":"2009","journal-title":"BMC Biotechnol."},{"key":"2026102103084565500_cit22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.colsurfb.2016.06.034","article-title":"Phenylboronic acid-functionalized polyamidoamine-mediated Bcl-2 siRNA delivery for inhibiting the cell proliferation","volume":"146","author":"Wu","year":"2016","journal-title":"Colloids Surf., B"},{"key":"2026102103084565500_cit23","doi-asserted-by":"publisher","first-page":"8037","DOI":"10.2147\/ijn.s329433","article-title":"Phenylboronic acid-modified polyamidoamine mediated the transfection of Polo-Like Kinase-1 siRNA to achieve an anti-tumor efficacy","volume":"16","author":"Gong","year":"2021","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"2026102103084565500_cit24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw8922","article-title":"A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing","volume":"5","author":"Liu","year":"2019","journal-title":"Sci. Adv."},{"issue":"3","key":"2026102103084565500_cit25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3390\/pharmaceutics14030655","article-title":"An evaluation of CXCR4 targeting with PAMAM dendrimer conjugates for oncologic applications","volume":"14","author":"Lesniak","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026102103084565500_cit26","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.2147\/ijn.s36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles","volume":"7","author":"Fro\u0308hlich","year":"2012","journal-title":"Int. J. Nanomed."},{"issue":"14","key":"2026102103084565500_cit27","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/c6cs00636a","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"issue":"Suppl","key":"2026102103084565500_cit28","first-page":"15","article-title":"Optimization of a method to prepare liposomes containing HER2\/Neu-derived peptide as a vaccine delivery system for breast cancer","volume":"13","author":"Shariat","year":"2014","journal-title":"Iran. J. Pharm. Res."},{"issue":"7","key":"2026102103084565500_cit29","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1021\/acs.biomac.8b00589","article-title":"Importance of encapsulation stability of nanocarriers with high drug loading capacity for increasing in vivo therapeutic efficacy","volume":"19","author":"Palanikumar","year":"2018","journal-title":"Biomacromolecules"},{"issue":"6","key":"2026102103084565500_cit30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s11095-022-03229-7","article-title":"PAMAM versus PEI complexation for siRNA delivery: interaction with model lipid membranes and cellular uptake","volume":"39","author":"Chang","year":"2022","journal-title":"Pharm. Res."},{"issue":"8","key":"2026102103084565500_cit31","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: siRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J. Cell Sci."},{"issue":"12","key":"2026102103084565500_cit32","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1039\/c4nr00018h","article-title":"Enhancing endosomal escape for nanoparticle mediated siRNA delivery","volume":"6","author":"Ma","year":"2014","journal-title":"Nanoscale"},{"issue":"17","key":"2026102103084565500_cit33","doi-asserted-by":"publisher","first-page":"2206306","DOI":"10.1002\/advs.202206306","article-title":"High-performance multi-dynamic bond cross-linked hydrogel with spatiotemporal siRNA delivery for Gene-Cell combination therapy of intervertebral disc degeneration","volume":"10","author":"Chen","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"2026102103084565500_cit34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2012.04.036","article-title":"Protein-based nanocarriers as promising drug and gene delivery systems","volume":"161","author":"Elzoghby","year":"2012","journal-title":"J. Contr. Release"}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00488","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/2101\/68629546\/bc6c00488.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/2101\/68629546\/bc6c00488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:11:21Z","timestamp":1792570281000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/10\/2101\/5437135\/Co-delivery-of-siPD-L1-and-Tat-HSPB1-by-G5PBA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00488","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}